Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Change in Acquisitions & Divestments (2022 - 2025)

Historic Change in Acquisitions & Divestments for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $125.5 million.

  • Praxis Precision Medicines' Change in Acquisitions & Divestments rose 10405.69% to $125.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $309.3 million, marking a year-over-year increase of 37940.49%. This contributed to the annual value of $123.0 million for FY2024, which is 21544.87% up from last year.
  • As of Q3 2025, Praxis Precision Medicines' Change in Acquisitions & Divestments stood at $125.5 million, which was up 10405.69% from $59.3 million recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Change in Acquisitions & Divestments registered a high of $125.5 million during Q3 2025, and its lowest value of $3.0 million during Q2 2024.
  • Its 4-year average for Change in Acquisitions & Divestments is $49.4 million, with a median of $53.2 million in 2022.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first crashed by 8571.43% in 2023, then skyrocketed by 187656.67% in 2025.
  • Praxis Precision Medicines' Change in Acquisitions & Divestments (Quarter) stood at $22.6 million in 2022, then tumbled by 77.87% to $5.0 million in 2023, then soared by 1070.0% to $58.5 million in 2024, then soared by 114.61% to $125.5 million in 2025.
  • Its last three reported values are $125.5 million in Q3 2025, $59.3 million for Q2 2025, and $66.0 million during Q1 2025.